| 1. |
- Ruilope, LM, et al.
(author)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
In: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Journal article (peer-reviewed)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 3. |
- Tariq, N., et al.
(author)
-
A Novel Kite-Shaped Chipless RFID Tag for Low-Profile Applications
- 2019
-
In: IETE Journal of Research. - : Informa UK Limited. - 0377-2063 .- 0974-780X. ; , s. 1-8
-
Journal article (peer-reviewed)abstract
- In this paper a novel, compact 10-bit chipless radio frequency identification (RFID) tag with stable readable characteristics is proposed. The tag is composed of several concentric novel kite-shaped loop resonators. The desired data sequence is obtained by the insertion or removal of nested elements, offering a 1:1 data bit to resonance correspondence. Each data sequence is encoded in the spectral domain of the tag. The proposed tag shows operability at different polarizations and incident angles of the impinging electromagnetic waves. Operating within the ultra-wideband (UWB), the tag is realized on the Roger RT/duroid® 5880 substrate having physical dimensions of 13.55 × 13.55 mm2. The measurement results of the design reveal a high code density and spectral efficiency of 5.44 bits/cm2 and 2 bits/GHz, respectively. The compact and robust passive chipless RFID tag having scalable data storage potential can be deployed in numerous low-profile applications such as those of wearable and healthcare.
|
|
